{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:55:07Z","timestamp":1792234507237,"version":"4.4.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"publisher","award":["NSTC 114-2314-B-075-005"],"award-info":[{"award-number":["NSTC 114-2314-B-075-005"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V113B-021"],"award-info":[{"award-number":["V113B-021"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yin Shu-Tien Foundation Taipei Veterans General Hospital-National Yang Ming Chiao Tung University Excellent Physician Scientists Cultivation Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Steroidal mineralocorticoid receptor antagonists (MRAs), including spironolactone, effectively treat resistant hypertension, reduce proteinuria and lower mortality in heart failure with reduced ejection fraction. However, their long-term effects in chronic kidney disease (CKD) remain unclear. This study investigated spironolactone's impact on end-stage renal disease (ESRD), major adverse cardiovascular events (MACE), hyperkalemia and mortality in CKD patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective hospital-based cohort study enrolled patients with CKD stage 3\u20135 between 1 January 2011 and 30 June 2023. The patients were classified as spironolactone users or nonusers, with each user matched to two nonusers by propensity scores. The outcomes of interest included ESRD, MACE, all-cause mortality and severe hyperkalemia. MACE include nonfatal stroke, nonfatal myocardial infarction and cardiovascular death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After propensity score matching, 2711 spironolactone users and 5422 nonusers were included in this analysis. Spironolactone users exhibited higher risks of all-cause mortality [adjusted hazard ratio (aHR) 1.23; 95% confidence interval (CI) 1.11\u20131.37] and severe hyperkalemia (aHR 1.44; 95% CI 1.24\u20131.68) than nonusers. However, there was a lower risk of MACE (aHR 0.90; 95% CI 0.82\u20130.99), primarily due to a significant reduction in stroke risk (aHR 0.79; 95% CI 0.71\u20130.88). The risk of ESRD was similar between the two groups (aHR 1.09; 95% CI 0.85\u20131.38).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with CKD, spironolactone use was associated with a decreased risk of stroke but increased risks of severe hyperkalemia and all-cause mortality, while the risk of ESRD remained unchanged. Individualized clinical decision-making and appropriate dose adjustment are important to balance the potential benefits and risks associated with spironolactone therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf247","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:35:22Z","timestamp":1754393722000},"source":"Crossref","is-referenced-by-count":5,"title":["Effect of spironolactone on cardiovascular and renal outcomes in patients with chronic kidney disease"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4101-8824","authenticated-orcid":false,"given":"Tz-Heng","family":"Chen","sequence":"first","affiliation":[{"name":"Taipei Veterans General Hospital Division of Nephrology, Department of Medicine, , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]},{"name":"Institute of Emergency and Critical Care Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-3728","authenticated-orcid":false,"given":"Shuo-Ming","family":"Ou","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital Division of Nephrology, Department of Medicine, , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]},{"name":"Institute of Clinical Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8058-073X","authenticated-orcid":false,"given":"Kuan-Hsun","family":"Lin","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital Department of Information Management, , Taipei ,","place":["Taiwan"]},{"name":"National Taipei University of Nursing and Department of Information Management, , Health Sciences, Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ho","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital Division of Nephrology, Department of Medicine, , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6940-9651","authenticated-orcid":false,"given":"Wei-Cheng","family":"Tseng","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital Division of Nephrology, Department of Medicine, , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Chia","family":"Chu","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital Department of Information Management, , Taipei ,","place":["Taiwan"]},{"name":"National Taipei University of Nursing and Department of Information Management, , Health Sciences, Taipei ,","place":["Taiwan"]},{"name":"Big Data Center, Taipei Veterans General Hospital , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-2081","authenticated-orcid":false,"given":"Der-Cherng","family":"Tarng","sequence":"additional","affiliation":[{"name":"Taipei Veterans General Hospital Division of Nephrology, Department of Medicine, , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]},{"name":"National Yang Ming Chiao Tung University Department and Institute of Physiology, , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"2025090405012754900_bib1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"key":"2025090405012754900_bib2","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S2214-109X(24)00050-0","article-title":"The major global burden of chronic kidney disease","volume":"12","author":"Jadoul","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2025090405012754900_bib3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2025090405012754900_bib4","doi-asserted-by":"publisher","first-page":"100604","DOI":"10.1016\/j.xkme.2023.100604","article-title":"CKD progression risk and subsequent cause of death: a population-based cohort study","volume":"5","author":"Rai","year":"2023","journal-title":"Kidney Med"},{"key":"2025090405012754900_bib5","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of death in patients with reduced kidney function","volume":"26","author":"Thompson","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025090405012754900_bib6","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","article-title":"Mineralocorticoid receptor antagonism in chronic kidney disease","volume":"6","author":"Georgianos","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025090405012754900_bib7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2025090405012754900_bib8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025090405012754900_bib9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2025090405012754900_bib10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amjmed.2018.09.011","article-title":"Spironolactone and outcomes in older patients with heart failure and reduced ejection fraction","volume":"132","author":"Bayoumi","year":"2019","journal-title":"Am J Med"},{"key":"2025090405012754900_bib11","doi-asserted-by":"publisher","first-page":"e018827","DOI":"10.1161\/JAHA.120.018827","article-title":"Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension","volume":"9","author":"Tsujimoto","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025090405012754900_bib12","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2025090405012754900_bib13","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1210\/clinem\/dgad144","article-title":"Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes","volume":"108","author":"Oiwa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090405012754900_bib14","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025090405012754900_bib15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2025090405012754900_bib16","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025090405012754900_bib17","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025090405012754900_bib18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2025090405012754900_bib19","doi-asserted-by":"publisher","first-page":"E531","DOI":"10.1152\/ajpendo.00022.2023","article-title":"Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"324","author":"Yao","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2025090405012754900_bib20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/dom.14696","article-title":"Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes","volume":"24","author":"DeFronzo","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2025090405012754900_bib21","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"2025090405012754900_bib22","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025090405012754900_bib23","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms20205214","article-title":"Endothelial dysfunction in primary aldosteronism","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025090405012754900_bib24","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"key":"2025090405012754900_bib25","first-page":"200138","article-title":"Relationship between plasma aldosterone levels and arterial stiffness parameters in hypertensive patients with subclinical vascular damage","volume":"14","author":"Petramala","year":"2022","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"2025090405012754900_bib26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.mvr.2006.12.001","article-title":"Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats","volume":"73","author":"Rigsby","year":"2007","journal-title":"Microvasc Res"},{"key":"2025090405012754900_bib27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.brainres.2016.02.034","article-title":"Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor","volume":"1637","author":"Dinh","year":"2016","journal-title":"Brain Res"},{"key":"2025090405012754900_bib28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/ph16010057","article-title":"Association between use of spironolactone and risk of stroke in hypertensive patients: a cohort study","volume":"16","author":"Cai","year":"2022","journal-title":"Pharmaceuticals"},{"key":"2025090405012754900_bib29","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/pds.3748","article-title":"Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor\/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort","volume":"24","author":"Abbas","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025090405012754900_bib30","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/ndt\/gfg295","article-title":"Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone","volume":"18","author":"Cruz","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2025090405012754900_bib31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2025090405012754900_bib32","doi-asserted-by":"publisher","first-page":"iii12","DOI":"10.1093\/ndt\/gfz231","article-title":"Hyperkalemia in patients with chronic renal failure","volume":"34","author":"Seliger","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2025090405012754900_bib33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.xkme.2020.12.006","article-title":"Metabolic acidosis in CKD: a review of recent findings","volume":"3","author":"Melamed","year":"2021","journal-title":"Kidney Med"},{"key":"2025090405012754900_bib34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.xkme.2021.04.011","article-title":"Metabolic acidosis and cardiovascular disease in CKD","volume":"3","author":"Collister","year":"2021","journal-title":"Kidney Med"},{"key":"2025090405012754900_bib35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1053\/j.ackd.2017.06.005","article-title":"Adverse effects of the metabolic acidosis of chronic kidney disease","volume":"24","author":"Kraut","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025090405012754900_bib36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.1980.42","article-title":"Spironolactone and amiloride in hypertensive patients with and without aldosterone excess","volume":"27","author":"Hoefnagels","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"2025090405012754900_bib37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40360-020-00431-4","article-title":"Furosemide and spironolactone doses and hyponatremia in patients with heart failure","volume":"21","author":"Velat","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"2025090405012754900_bib38","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1210\/clinem\/dgaa547","article-title":"Risk of adverse clinical outcomes in hyponatremic adult patients hospitalized for acute medical conditions: a population-based cohort study","volume":"105","author":"Kutz","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2025090405012754900_bib39","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/archinte.166.7.781","article-title":"Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction","volume":"166","author":"Goldberg","year":"2006","journal-title":"Arch Intern Med"},{"key":"2025090405012754900_bib40","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.xkme.2022.100554","article-title":"Dysnatremias, mortality, and kidney failure in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"4","author":"Hassanein","year":"2022","journal-title":"Kidney Med"},{"key":"2025090405012754900_bib41","doi-asserted-by":"publisher","first-page":"36817","DOI":"10.1038\/srep36817","article-title":"Hyponatremia is associated with fluid imbalance and adverse renal outcome in chronic kidney disease patients treated with diuretics","volume":"6","author":"Lim","year":"2016","journal-title":"Sci Rep"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf247\/63969244\/sfaf247.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/9\/sfaf247\/63969244\/sfaf247.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/9\/sfaf247\/63969244\/sfaf247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T09:01:36Z","timestamp":1756976496000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf247\/8223405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf247","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,6]]},"article-number":"sfaf247"}}